RecruitingNCT06831071

Evaluation of Hypoxia in Primary Melanoma

Studying Neuroendocrine neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Yana Najjar
Principal Investigator
Yana M Najjar, MD
UPMC Hillman Cancer Center
Intervention
Pimonidazole(drug)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

Hypoxyprobe

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06831071 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine neoplasm

← Back to all trials